Study raises red flags over long-term effectiveness of popular weight loss drugs like Ozempic
Ozempic, Mounjaro, and Zepbound can drive impressive weight loss, but stopping them is often followed by rapid weight regain. Researchers found that people regain weight faster after quitting these drugs than after diet and exercise alone. Improvements in heart health and diabetes risk also tend to reverse within a few years. The results suggest long-term success may require more than medication alone.
Tirzepatide Safety Warning; Nurse Charged Over Fake GLP-1s; Revised Afrezza Dosing
(MedPage Today) — Tirzepatide (Mounjaro, Zepbound) users should never share KwikPens due to risk for transmission of blood-borne pathogens, the FDA warned in an updated label.
GLP-1 medications for weight loss accounted for more than 7% of all…
Roche’s 22% Weight Loss Benefit Seals GLP-1’s Phase III Plans, Boosts Zealand Combo
Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.
Menopause Hormone Therapy May Boost GLP-1 Drug Benefits
(MedPage Today) — Postmenopausal women on the GLP-1 medication tirzepatide (Zepbound) for obesity lost more weight if they were also using menopause hormone therapy, a retrospective cohort study indicated.
Among 120 women with overweight or obesity…
The 5 Worst Things You Can Do While Taking a GLP-1 for Weight Loss
According to doctors, making a misstep is easier than you may think.
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
South San Francisco, CA — January 26, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP…
Why I’m Choosing Not to Take GLP-1s, Even Though Everyone Expects Me To
I’m a candidate for the meds, but they’re not for me—at least for now.
Big Pharma shops Chinese biotechs to stock GLP-1 pipelines
Novo, Regeneron and Pfizer all landed weight loss deals with China-based companies last year.
Hormone therapy combined with tirzepatide linked to greater weight loss after menopause
A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause.
GLP-1 medications: A comprehensive overview
With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.